Empowering Melatonin Therapeutics with Drosophila Models
| Autor: | Anna Park, Shana McSweeney, Cassandra Millet-Boureima, Chiara Gamberi, Caroline C. Ennis, Jurnee Jamison |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
ved/biology
PKD ved/biology.organism_classification_rank.species Neurodegeneration Regulator neurodegeneration melatonin Disease Biology Mitochondrion medicine.disease medicine.disease_cause Melatonin Drosophila longevity medicine oxidative stress Medicine Model organism Neuroscience Function (biology) Oxidative stress hormones hormone substitutes and hormone antagonists medicine.drug |
| Zdroj: | Diseases, Vol 9, Iss 67, p 67 (2021) |
| ISSN: | 2079-9721 |
| Popis: | Melatonin functions as a central regulator of cell and organismal function as well as a neurohormone involved in several processes, e.g., the regulation of the circadian rhythm, sleep, aging, oxidative response, and more. As such, it holds immense pharmacological potential. Receptor-mediated melatonin function mainly occurs through MT1 and MT2, conserved amongst mammals. Other melatonin-binding proteins exist. Non-receptor-mediated activities involve regulating the mitochondrial function and antioxidant cascade, which are frequently affected by normal aging as well as disease. Several pathologies display diseased or dysfunctional mitochondria, suggesting melatonin may be used therapeutically. Drosophila models have extensively been employed to study disease pathogenesis and discover new drugs. Here, we review the multiple functions of melatonin through the lens of functional conservation and model organism research to empower potential melatonin therapeutics to treat neurodegenerative and renal diseases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|